Novo Nordisk and UnitedHealth have seen their share prices fall in recent weeks.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA13 Aug 2025, 19:45 UTC
AI-generated source summary
The analysis compares Novo Nordisk (NOVOb) and UnitedHealth (UNH), both near 52-week lows. Revenue growth, profit margins, and returns on invested capital were analyzed. For Novo Nordisk the intrinsic value is estimated around $127.47 with the current price at $49.87. United Health's intrinsic value is estimated at $434, significantly above its market price of $252.37. Revenue growth is expected to be better for NOVO than UNH, operating margin is 47.7% and improving for NOVO, and WACC is 8.14%. However, Novo faces competition from Eli Lilly and compounded medications. UNH faces customer loss due to pricing and market exits, their OC to WACC ratio is below 1.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.